Ipamorelin + AOD-9604 Stack: Complete Protocol, Doses, and Timing

What Are These Two Peptides and Why Stack Them?

Ipamorelin is a selective growth hormone secretagogue that binds the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus, triggering a clean, pulsatile spike in endogenous growth hormone without meaningful cortisol or prolactin elevation, a key differentiator from older GHRPs such as GHRP-2 or GHRP-6. AOD-9604 is the synthetic C-terminal fragment of human growth hormone spanning amino acids 176 to 191. It does not bind the GH receptor in a way that raises IGF-1, but it does activate fat-cell beta-3 adrenergic pathways that promote lipolysis and inhibit lipogenesis.

Stacking them is logical on paper: ipamorelin raises endogenous GH, which itself has lipolytic signaling, while AOD-9604 delivers a more direct, receptor-targeted lipolytic stimulus. Used together, the two peptides could address fat loss through two independent mechanisms rather than one.

No human RCT has tested this specific combination. The evidence base is a mix of individual-peptide mechanistic data, animal studies, and practitioner-reported clinical observations.

Ipamorelin: Mechanism at the Pituitary

Ipamorelin binds GHSR-1a with high selectivity. In an in vitro receptor-selectivity study, ipamorelin produced growth hormone release comparable to GHRP-6 but with negligible ACTH or cortisol co-secretion at doses up to 10x the GH-effective dose. Growth hormone, once released, promotes lipolysis in adipose tissue through hormone-sensitive lipase activation and suppresses adipogenesis, effects well-described in a 2010 review in Endocrine Reviews [1].

AOD-9604: Direct Lipolysis Without IGF-1 Elevation

AOD-9604 was originally developed by Monash University researchers studying the anti-obesity potential of GH fragments. In obese mouse models, AOD-9604 reduced body weight by approximately 50% compared with controls over a 19-day period without affecting blood glucose or insulin sensitivity in the same study [2]. The compound advanced to Phase II human trials for obesity (Clinuvel / METABOL-1 program), where it was found safe but ultimately did not meet primary endpoints for weight loss at the doses and durations studied. The FDA granted AOD-9604 GRAS (Generally Recognized as Safe) status as a food ingredient in 2014, though that designation does not extend to injectable pharmaceutical use [3].

Ipamorelin + AOD-9604: Proposed Mechanisms in Combination

When both peptides are administered together, three mechanistic pathways are active simultaneously.

First, ipamorelin drives a pulsatile GH spike. GH acts on adipocytes to upregulate hormone-sensitive lipase, increasing free fatty acid release into circulation. Second, AOD-9604 activates beta-3 adrenergic receptors on fat cells directly, a pathway that is at least partly independent of GH receptor binding. Third, the suppression of lipogenesis attributed to AOD-9604 means newly released fatty acids are less likely to be re-esterified back into triglycerides.

This triple action is the theoretical basis for additive benefit. Whether it is actually additive or merely overlapping in humans is not yet established by controlled data.

Receptor-Level Independence

A 2000 study in Growth Hormone & IGF Research confirmed that AOD-9604 fragments retain lipolytic activity through a pathway distinct from full-length GH receptor activation, supporting the idea that combining a GH secretagogue with AOD-9604 targets different cellular entry points [4].

IGF-1 Sparing

One practical advantage of using AOD-9604 rather than exogenous recombinant GH for the lipolytic component is that AOD-9604 does not raise IGF-1. Chronically elevated IGF-1 has been associated with increased cancer risk in observational cohorts, as noted in a meta-analysis of 17 prospective studies in The Lancet Oncology [5]. Ipamorelin's pulsatile, short-duration GH spikes keep IGF-1 elevation modest compared with continuous exogenous GH administration.

Complete Dosing Protocol

No consensus guideline exists for this combination. The protocol below represents the most commonly reported practitioner framework, synthesized from peer-reviewed pharmacokinetic data on each compound individually.

Ipamorelin Dosing

The standard range used in clinical peptide protocols is 200 to 300 mcg per injection, administered subcutaneously. Practitioners typically run 1 to 3 injections per day. For fat-loss goals, two injections daily, one 30 minutes before morning fasted cardio and one at bedtime, align with natural GH secretion patterns. GH is secreted in pulses roughly every 3 to 5 hours in healthy adults, with the largest pulse occurring in early sleep, as described in a landmark 1990 NEJM study on GH pulsatility [6].

Avoid eating for at least 60 minutes after each ipamorelin injection. Insulin and high blood glucose blunt GH secretion; carbohydrate ingestion within that window could reduce the GH pulse by 60 to 70% based on GH suppression studies using oral glucose tolerance tests [7].

AOD-9604 Dosing

The most-reported dose in clinical peptide contexts is 300 to 500 mcg once daily, injected subcutaneously into the abdominal fat layer. The fasted morning window is preferred because beta-adrenergic lipolytic signaling is more active in the presence of low insulin. Phase II human trial data for obesity used oral AOD-9604 at 1 mg and 9 mg per day, routes and doses that are not directly comparable to injectable protocols [8].

Injection Timing Table

| Time | Peptide | Dose | Notes | |---|---|---|---| | Morning, fasted | AOD-9604 | 300 to 500 mcg SC | Inject 15 to 20 min before exercise or activity | | Morning, fasted | Ipamorelin | 200 to 300 mcg SC | Can be given at same site, separate syringe | | Pre-bed | Ipamorelin | 200 to 300 mcg SC | Align with nocturnal GH pulse; no food 2h prior |

Reconstitution

Both peptides are typically supplied as lyophilized powder. Use bacteriostatic water at 1 to 2 mL per vial. A standard reconstitution for a 5 mg AOD-9604 vial with 2 mL bacteriostatic water yields 250 mcg per 0.1 mL drawn. Store reconstituted peptides refrigerated at 2 to 8°C and use within 28 days. Never freeze a reconstituted solution, as repeated freeze-thaw cycles degrade peptide integrity.

Cycle Length and Cycling Strategy

Most practitioners report running this stack for 8 to 12 weeks. Longer cycles theoretically risk desensitization of the GHSR-1a receptor, though ipamorelin demonstrates less tachyphylaxis than GHRP-6 in receptor studies [9]. A common approach is 5 days on, 2 days off each week to preserve receptor sensitivity, or a full 8-week cycle followed by 4 weeks off.

AOD-9604 has not been studied for receptor downregulation over repeated cycles in humans. Given its mechanism operates partly through beta-3 adrenergic pathways, the same tachyphylaxis concerns that apply to sympathomimetics are theoretically relevant, though no clinical data quantify this risk for AOD-9604 specifically.

Stacking with CJC-1295

Some protocols add CJC-1295 (without DAC) to ipamorelin to amplify the GH pulse. CJC-1295 is a GHRH analogue that acts synergistically with ipamorelin's GHRP effect. In a published dose-escalation study, CJC-1295 with DAC produced sustained GH elevation of 2 to 10 fold above baseline lasting days [10]. The no-DAC version is preferred for pulsatile protocols because its half-life of approximately 30 minutes matches the ipamorelin injection window. Adding CJC-1295 to an ipamorelin-AOD-9604 stack increases complexity and GH exposure; this should only be done under direct physician supervision with baseline IGF-1 monitoring.

Expected Outcomes and Timeline

Reported outcomes from practitioner-observed cases and individual-peptide trial data suggest:

• Weeks 1 to 2: Improved sleep quality and mild increase in recovery speed, attributed to ipamorelin's nocturnal GH pulse.
• Weeks 3 to 4: Reduction in subcutaneous fat, particularly in the abdominal region, consistent with beta-3 adrenergic lipolysis. Some users report 0.5 to 1 lb of fat loss per week when diet is controlled.
• Weeks 6 to 12: Progressive body composition improvement with lean mass preservation. In AOD-9604 animal studies, fat-mass reduction was accompanied by no change in lean mass or organ weight [2].

These timelines are extrapolated from individual-peptide data. The combination has not been studied prospectively with DEXA or MRI body-composition endpoints in humans.

Weight-loss results from this stack will be modest compared with GLP-1 receptor agonists. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo [11]. Peptide stacks like ipamorelin-AOD-9604 are not dose-equivalent alternatives to semaglutide for significant obesity; they may be more appropriate as adjuncts in leaner individuals (BMI <30) pursuing body recomposition rather than large-scale weight loss.

Side Effects and Safety Monitoring

Ipamorelin Side Effects

Ipamorelin is generally well-tolerated in human use. The most commonly reported adverse effects are:

• Transient flushing or headache in the first 1 to 2 weeks, likely from the initial GH spike.
• Mild fluid retention, particularly in the extremities, which typically resolves after the first cycle week.
• Local injection-site irritation, especially with concentrated reconstitutions.

Because GH stimulates insulin resistance at supraphysiologic levels, fasting glucose should be checked at baseline and at 4 to 6 weeks. A 2000 review in Journal of Clinical Endocrinology & Metabolism noted that pharmacological GH elevation consistently raises fasting glucose by approximately 0.4 to 0.6 mmol/L [12].

AOD-9604 Side Effects

The Phase II clinical trial safety data for oral AOD-9604 at up to 9 mg/day found no significant adverse events versus placebo. Injectable AOD-9604 has not been studied in a formal human safety trial. Reported practitioner observations include mild local injection-site redness and occasional headache at doses above 500 mcg.

Who Should Not Use This Stack

This combination is contraindicated or requires specialist clearance in the following groups:

• Active malignancy or personal history of hormone-sensitive cancers.
• Pregnancy or breastfeeding.
• Untreated hypothyroidism (GH secretion is impaired in hypothyroid states, and GH replacement can worsen subclinical hypothyroidism).
• Diabetics on insulin or sulfonylureas, given ipamorelin's potential to reduce insulin sensitivity.
• Age <18 years. Open growth plates could theoretically be affected by GH stimulation, though ipamorelin's GH pulses are modest.

Laboratory Monitoring Recommendations

Baseline labs before starting this stack should include: IGF-1, fasting glucose, HbA1c, thyroid panel (TSH, free T4), and a basic metabolic panel. Repeat IGF-1 and fasting glucose at weeks 6 and 12. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency states that IGF-1 should be kept within the age-adjusted reference range during any GH-axis intervention [13].

Regulatory and Ethical Considerations

Neither ipamorelin nor AOD-9604 is FDA-approved as a drug for human use in any indication. Ipamorelin is listed on the World Anti-Doping Agency (WADA) prohibited list as a peptide hormone and growth factor. AOD-9604's GRAS status from the FDA covers it as a food ingredient only, not as an injectable pharmaceutical [3]. Both compounds are sold legally as research chemicals in many jurisdictions, but their sale for human use is a legal gray area in the United States.

The FDA's 2023 crackdown on compounded peptides removed several peptides from allowable compounding lists. Patients considering this stack should consult with a physician in a state that permits peptide prescribing under appropriate informed-consent frameworks [14].

As the American Academy of Anti-Aging Medicine has stated in its practitioner guidance: "Off-label and investigational peptide use requires rigorous informed consent, baseline laboratory assessment, and longitudinal monitoring to meet the standard of individualized patient care."

Practical Injection Guide

Subcutaneous injection technique affects both comfort and absorption. Use a 29 to 31 gauge, 0.5-inch insulin syringe for all peptide injections. Pinch a fold of abdominal skin 2 to 3 inches from the navel, insert at a 45-degree angle, inject slowly, and hold for 5 seconds before withdrawing. Rotate injection sites across a 4-quadrant abdominal grid to prevent lipohypertrophy. Allow the vial to reach room temperature before drawing; cold peptide solutions increase injection discomfort.

Do not mix ipamorelin and AOD-9604 in the same syringe unless sterility and chemical compatibility have been confirmed by a compounding pharmacist.